Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. - Raskin,P.; Rappaport,E.B.; Cole,S.T.; Yan,Y.; Patwardhan,R.; Freed,M.I. (Diabetologia, 2000)